Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals has faced notable volatility, with its stock price declining significantly today after an initial gain. The company has underperformed compared to its sector and the broader market over recent days, experiencing consecutive losses. Despite today's downturn, it has shown positive performance over the past month.

Jagsonpal Pharmaceuticals has recently experienced a change in evaluation following a strong financial performance in Q3 FY24-25, highlighted by a 179.14% increase in net profit. The company has shown consistent growth over three quarters, with net sales reaching Rs 148.72 crore, up 41.56%.

Jagsonpal Pharmaceuticals has faced a challenging trading day, with its stock price declining significantly and underperforming its sector. Despite recent losses, the company has shown resilience over the past month, outperforming the Sensex. Technical indicators reveal a mixed performance, with the stock above several moving averages but below the 5-day average.

Jagsonpal Pharmaceuticals has demonstrated strong market performance, gaining 9.82% on February 6, 2025, significantly outperforming the Sensex. The stock reached an intraday high of Rs 269.75 and has shown a 10.53% increase over the past month, reflecting its competitive position in the pharmaceuticals sector.

Jagsonpal Pharmaceuticals has recently adjusted its evaluation, reflecting strong financial performance in Q3 FY24-25, with a significant increase in net profit and sales. The company maintains a low debt-to-equity ratio and has shown consistent positive results over the past three quarters, despite facing some market challenges.

Jagsonpal Pharmaceuticals has demonstrated notable activity, with a significant stock increase on January 30, 2025. The stock has shown a positive trend over the past three days, outperforming the broader market. Despite some intraday volatility, it remains above several key moving averages, indicating resilience in a fluctuating market.

Jagsonpal Pharmaceuticals has seen a notable rise in stock performance, gaining 8.82% on January 29, 2025, and outperforming its sector. The stock has shown a consistent upward trend over two days, accumulating an 11.11% return, while facing challenges with a monthly decline amid broader market fluctuations.

Jagsonpal Pharmaceuticals experienced significant trading activity on January 28, 2025, rebounding after two days of decline. The stock reached an intraday high of Rs 233.55, showcasing high volatility. Despite a recent monthly decline, it outperformed its sector, highlighting its fluctuating market position.

Jagsonpal Pharmaceuticals has faced notable volatility, with its stock price declining significantly today, marking a two-day loss of 13.55%. Despite an initial gain, the stock reversed direction, reflecting substantial intraday fluctuations. Over the past month, it has underperformed compared to the broader market, indicating ongoing challenges.

Jagsonpal Pharmaceuticals has experienced notable trading activity, gaining 8.02% on January 24, 2025, and outperforming its sector. The stock opened with a significant gap and reached an intraday high, showcasing high volatility. It remains above several moving averages, despite a slight decline over the past month.

Jagsonpal Pharmaceuticals experienced significant trading activity on January 23, 2025, with a notable increase following a prior two-day gain. The stock outperformed its sector and the Sensex, despite a decline over the past month. Technically, it is positioned above several moving averages but below the 50-day average.

Jagsonpal Pharmaceuticals reported its third-quarter financial results for FY24-25, revealing a Profit After Tax of Rs 12.81 crore, the highest in five quarters. Net sales reached Rs 74.03 crore, indicating significant growth compared to previous quarters, reflecting a positive trend in the company's financial performance.

Jagsonpal Pharmaceuticals experienced a notable rise on January 14, 2025, following four days of decline. The stock reached an intraday high, trading above its long-term moving averages while facing a monthly decline. This performance may suggest a shift in market sentiment within the pharmaceuticals sector.

Jagsonpal Pharmaceuticals has recently undergone a revision in its score, reflecting ongoing challenges in the pharmaceuticals sector. The stock has been added to MarketsMOJO's list amid a notable decline in performance metrics, including a significant drop over the past month, contrasting sharply with broader market trends.

Jagsonpal Pharmaceuticals Ltd. has reached a new milestone as its stock price hit a 52-week high on November 29, 2024. The stock has been performing well, with a 2.58% gain today and a total return of 8.85% in the last two days. It has also outperformed the sector by 5.05%. The company's strong growth and potential in the market is evident from its positive trend and remarkable 88.79% increase in stock price in the past year.

On November 29, 2024, Jagsonpal Pharmaceuticals ., a smallcap company in the pharmaceuticals and drugs industry, saw a 9.18% increase in its stock price, outperforming the sector by 1.56%. The stock has been on a consecutive gain for 2 days and is trading higher than its moving averages. It has also outperformed the Sensex and has a potential for future growth.

Jagsonpal Pharmaceuticals Ltd., a smallcap company in the pharmaceuticals and drugs industry, has seen a surge in its stock price, reaching an all-time high of Rs 724 on November 29, 2024. The stock has outperformed the sector and has been on a consecutive gain for the last 2 days, with a 5.28% increase. The company has also shown a remarkable performance in the past year, outperforming the market with an 88.21% increase in its stock price.

Jagsonpal Pharmaceuticals Ltd., a smallcap company in the pharmaceuticals and drugs industry, has hit a 52-week and all-time high of Rs.688.5. According to MarketsMOJO, the stock call for Jagsonpal Pharmaceuticals is 'Hold', indicating steady performance in the near future. The stock has underperformed the sector today but is trading higher than its moving averages, and has outperformed the Sensex in the past year, showcasing its strong performance and growth potential.